Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

ABSTRACT:

Aims

To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia.

Design

Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia in November 2018.

Setting

Sydney, Melbourne and Hobart. Participants A total of 402 people who regularly use opioids interviewed December 2017 to March 2018.

Measurements

Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type,

SUBMITTER: Larance B 

PROVIDER: S-EPMC7292758 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature